Transcenta’s Post

View organization page for Transcenta, graphic

1,897 followers

lf you are attending #AACR2024, we invite you to come to our oral presentation, where we'll discuss development of Claudin18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-Claudin 18.2 monoclonal antibody Osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinoma.

To view or add a comment, sign in

Explore topics